JP2018518986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518986A5 JP2018518986A5 JP2018510313A JP2018510313A JP2018518986A5 JP 2018518986 A5 JP2018518986 A5 JP 2018518986A5 JP 2018510313 A JP2018510313 A JP 2018510313A JP 2018510313 A JP2018510313 A JP 2018510313A JP 2018518986 A5 JP2018518986 A5 JP 2018518986A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tumor
- composition according
- vector
- icp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000013598 vector Substances 0.000 claims 12
- 230000000174 oncolytic effect Effects 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 241001529453 unidentified herpesvirus Species 0.000 claims 9
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims 6
- 102000008730 Nestin Human genes 0.000 claims 6
- 108010088225 Nestin Proteins 0.000 claims 6
- 210000005055 nestin Anatomy 0.000 claims 6
- 101150096316 5 gene Proteins 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000002779 inactivation Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 claims 2
- 101150093191 RIR1 gene Proteins 0.000 claims 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 2
- 101150032932 UL39 gene Proteins 0.000 claims 2
- 108010067390 Viral Proteins Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 238000007917 intracranial administration Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156447P | 2015-05-04 | 2015-05-04 | |
| US62/156,447 | 2015-05-04 | ||
| PCT/US2016/030681 WO2016179226A1 (en) | 2015-05-04 | 2016-05-04 | Oncolytic hsv1 vector and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518986A JP2018518986A (ja) | 2018-07-19 |
| JP2018518986A5 true JP2018518986A5 (enExample) | 2019-02-21 |
| JP6865736B2 JP6865736B2 (ja) | 2021-04-28 |
Family
ID=57218316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510313A Active JP6865736B2 (ja) | 2015-05-04 | 2016-05-04 | 腫瘍溶解性ｈｓｖ１ベクターおよび使用法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10806761B2 (enExample) |
| EP (2) | EP3291841B1 (enExample) |
| JP (1) | JP6865736B2 (enExample) |
| KR (1) | KR102705177B1 (enExample) |
| CN (1) | CN108025088B (enExample) |
| AU (2) | AU2016257910B2 (enExample) |
| CA (1) | CA2988196C (enExample) |
| DK (1) | DK3291841T3 (enExample) |
| ES (1) | ES2903349T3 (enExample) |
| WO (1) | WO2016179226A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018169901A1 (en) * | 2017-03-13 | 2018-09-20 | Massachusetts Institute Of Technology | Synthetic promoters |
| KR101974169B1 (ko) | 2018-08-10 | 2019-04-30 | 의료법인 성광의료재단 | 재조합 단순 헤르페스 바이러스 및 이의 제조방법 |
| JP2022513639A (ja) * | 2018-11-29 | 2022-02-09 | ヴァイロジン バイオテック カナダ リミテッド | 低神経毒性ｈｓｖベクター |
| US12480097B2 (en) * | 2019-03-14 | 2025-11-25 | Research Institute At Nationwide Children's Hospital | Syncytial oncolytic herpes simplex mutants as potent cancer therapeutics |
| KR102333650B1 (ko) * | 2019-11-08 | 2021-12-01 | 한국해양과학기술원 | 신규한 인간 상피세포성장인자 융합 단백질 및 이의 용도 |
| IL303121A (en) * | 2020-12-04 | 2023-07-01 | Immvira Co Ltd | Oncolytic herpes simplex viruses type 1 for the treatment of brain tumors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| US7214515B2 (en) | 2001-01-05 | 2007-05-08 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic DNA inserts |
| WO2005080581A2 (en) | 2004-02-17 | 2005-09-01 | University Of Florida Research Foundation, Inc. | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression |
| JPWO2005103237A1 (ja) | 2004-03-31 | 2008-03-13 | 具紀 藤堂 | 組換え単純ヘルペスウイルスの作製方法 |
| MX2009006404A (es) * | 2006-12-18 | 2009-06-23 | Koninkl Philips Electronics Nv | Compresion y descompresion de imagen. |
| US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
| EP2307033A4 (en) * | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| WO2014078529A1 (en) * | 2012-11-14 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Oncolytic hsv1 vectors and methods of using the same |
-
2016
- 2016-05-04 CA CA2988196A patent/CA2988196C/en active Active
- 2016-05-04 EP EP16789977.2A patent/EP3291841B1/en active Active
- 2016-05-04 EP EP21197262.5A patent/EP3981438A1/en active Pending
- 2016-05-04 US US15/571,749 patent/US10806761B2/en active Active
- 2016-05-04 JP JP2018510313A patent/JP6865736B2/ja active Active
- 2016-05-04 WO PCT/US2016/030681 patent/WO2016179226A1/en not_active Ceased
- 2016-05-04 CN CN201680039678.8A patent/CN108025088B/zh active Active
- 2016-05-04 ES ES16789977T patent/ES2903349T3/es active Active
- 2016-05-04 AU AU2016257910A patent/AU2016257910B2/en active Active
- 2016-05-04 DK DK16789977.2T patent/DK3291841T3/da active
- 2016-05-04 KR KR1020177034916A patent/KR102705177B1/ko active Active
-
2021
- 2021-09-16 AU AU2021232778A patent/AU2021232778B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peters et al. | Designing herpes viruses as oncolytics | |
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Fukuhara et al. | Oncolytic virus therapy: A new era of cancer treatment at dawn | |
| MY197423A (en) | Recombinant herpes simplex virus and use thereof | |
| Liu et al. | ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | |
| Guo et al. | Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity | |
| Manservigi et al. | HSV recombinant vectors for gene therapy | |
| Lachmann | Herpes simplex virus‐based vectors | |
| Conradie et al. | Distinct polymorphisms in a single herpesvirus gene are capable of enhancing virulence and mediating vaccinal resistance | |
| CN109475613B (zh) | 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达 | |
| Russell et al. | Lytic promoters express protein during herpes simplex virus latency | |
| Chung et al. | The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma | |
| US20200171110A1 (en) | Hsv vector with reduced neurotoxicity | |
| Nakamura et al. | Regulation of herpes simplex virus γ 1 34.5 expression and oncolysis of diffuse liver metastases by Myb34. 5 | |
| Advani et al. | ReVOLT: radiation-enhanced viral oncolytic therapy | |
| JP2019517815A5 (enExample) | ||
| Glorioso | Herpes simplex viral vectors: late bloomers with big potential | |
| US20230365994A1 (en) | Hsv vectors with enhanced replication in cancer cells | |
| ES2903349T3 (es) | Vector del VHS1 oncolítico y métodos de uso | |
| Rezaei et al. | Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses | |
| Advani et al. | Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications | |
| Fujiwara et al. | Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer | |
| Hingorani et al. | Oncolytic viruses for potential osteosarcoma therapy | |
| Carson et al. | Oncolytic herpes simplex virus 1 (HSV-1) vectors: increasing treatment efficacy and range through strategic virus design | |
| Yao et al. | Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy |